These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32047002)

  • 1.
    Kobatake K; Ikeda KI; Nakata Y; Yamasaki N; Ueda T; Kanai A; Sentani K; Sera Y; Hayashi T; Koizumi M; Miyakawa Y; Inaba T; Sotomaru Y; Kaminuma O; Ichinohe T; Honda ZI; Yasui W; Horie S; Black PC; Matsubara A; Honda H
    Clin Cancer Res; 2020 Apr; 26(8):2065-2079. PubMed ID: 32047002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X chromosome protects against bladder cancer in females via a
    Kaneko S; Li X
    Sci Adv; 2018 Jun; 4(6):eaar5598. PubMed ID: 29928692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
    Degoricija M; Korac-Prlic J; Vilovic K; Ivanisevic T; Haupt B; Palada V; Petkovic M; Karaman I; Terzic J
    J Transl Med; 2019 Nov; 17(1):394. PubMed ID: 31779626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
    Ler LD; Ghosh S; Chai X; Thike AA; Heng HL; Siew EY; Dey S; Koh LK; Lim JQ; Lim WK; Myint SS; Loh JL; Ong P; Sam XX; Huang D; Lim T; Tan PH; Nagarajan S; Cheng CW; Ho H; Ng LG; Yuen J; Lin PH; Chuang CK; Chang YH; Weng WH; Rozen SG; Tan P; Creasy CL; Pang ST; McCabe MT; Poon SL; Teh BT
    Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.
    Yang J; Platt LT; Maity B; Ahlers KE; Luo Z; Lin Z; Chakravarti B; Ibeawuchi SR; Askeland RW; Bondaruk J; Czerniak BA; Fisher RA
    Oncotarget; 2016 Oct; 7(43):69159-69172. PubMed ID: 27713144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
    Nickerson ML; Dancik GM; Im KM; Edwards MG; Turan S; Brown J; Ruiz-Rodriguez C; Owens C; Costello JC; Guo G; Tsang SX; Li Y; Zhou Q; Cai Z; Moore LE; Lucia MS; Dean M; Theodorescu D
    Clin Cancer Res; 2014 Sep; 20(18):4935-48. PubMed ID: 25225064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
    PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
    Botrous S; Elmaghraby A; Achy SE; Mustafa Y; Abdel-Rahman S
    BMC Cancer; 2024 Aug; 24(1):971. PubMed ID: 39118085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of KDM6A mutation in bladder cancer immune escape.
    Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
    BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
    Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
    Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
    Liu L; Cui J; Zhao Y; Liu X; Chen L; Xia Y; Wang Y; Chen S; Sun S; Shi B; Zou Y
    Mol Cancer; 2021 May; 20(1):77. PubMed ID: 34006303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer.
    Qiu H; Makarov V; Bolzenius JK; Halstead A; Parker Y; Wang A; Iyer GV; Wise H; Kim D; Thayaparan V; Lindner DJ; Haber GP; Ting AH; Ren B; Chan TA; Arora V; Solit DB; Lee BH
    Cancer Res; 2023 Mar; 83(6):814-829. PubMed ID: 36638328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages.
    Li X; Zhang Q; Shi Q; Liu Y; Zhao K; Shen Q; Shi Y; Liu X; Wang C; Li N; Ma Y; Cao X
    J Autoimmun; 2017 Jun; 80():85-94. PubMed ID: 28284523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of
    Matar M; Prince G; Hamati I; Baalbaky M; Fares J; Aoude M; Matar C; Kourie HR
    Pharmacogenomics; 2023 Jun; 24(9):509-522. PubMed ID: 37458596
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
    Wei M; Wanibuchi H; Morimura K; Salim EI; Moku M; Doi K; Mitsuhashi M; Masuda C; Shen J; Kinoshita A; Fukushima S
    Anticancer Res; 2004; 24(2B):785-90. PubMed ID: 15161027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
    Özden-Yılmaz G; Savas B; Bursalı A; Eray A; Arıbaş A; Senturk S; Karaca E; Karakülah G; Erkek-Ozhan S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression.
    Park S; Rong L; Owczarek TB; Bernardo MD; Shoulson RL; Chua CW; Kim JY; Lankarani A; Chakrapani P; Syed T; McKiernan JM; Solit DB; Shen MM; Al-Ahmadie HA; Abate-Shen C
    Cancer Res; 2021 Oct; 81(20):5161-5175. PubMed ID: 34470779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele.
    Ozaki K; Sukata T; Yamamoto S; Uwagawa S; Seki T; Kawasaki H; Yoshitake A; Wanibuchi H; Koide A; Mori Y; Fukushima S
    Cancer Res; 1998 Sep; 58(17):3806-11. PubMed ID: 9731488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor‑infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
    Xue Y; Tong L; LiuAnwei Liu F; Liu A; Zeng S; Xiong Q; Yang Z; He X; Sun Y; Xu C
    Oncol Rep; 2019 Aug; 42(2):581-594. PubMed ID: 31233191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.